653 related articles for article (PubMed ID: 23760985)
21. Application of Physiologically Based Pharmacokinetic Modeling in Understanding Bosutinib Drug-Drug Interactions: Importance of Intestinal P-Glycoprotein.
Yamazaki S; Loi CM; Kimoto E; Costales C; Varma MV
Drug Metab Dispos; 2018 Aug; 46(8):1200-1211. PubMed ID: 29739809
[TBL] [Abstract][Full Text] [Related]
22. Unraveling pleiotropic effects of rifampicin by using physiologically based pharmacokinetic modeling: Assessing the induction magnitude of P-glycoprotein-cytochrome P450 3A4 dual substrates.
Pan X; Yamazaki S; Neuhoff S; Zhang M; Pilla Reddy V
CPT Pharmacometrics Syst Pharmacol; 2021 Dec; 10(12):1485-1496. PubMed ID: 34729944
[TBL] [Abstract][Full Text] [Related]
23. Use of a Physiologically Based Pharmacokinetic Model for Quantitative Prediction of Drug-Drug Interactions via CYP3A4 and Estimation of the Intestinal Availability of CYP3A4 Substrates.
Mano Y; Sugiyama Y; Ito K
J Pharm Sci; 2015 Sep; 104(9):3183-93. PubMed ID: 26045365
[TBL] [Abstract][Full Text] [Related]
24. Application of permeability-limited physiologically-based pharmacokinetic models: part II - prediction of P-glycoprotein mediated drug-drug interactions with digoxin.
Neuhoff S; Yeo KR; Barter Z; Jamei M; Turner DB; Rostami-Hodjegan A
J Pharm Sci; 2013 Sep; 102(9):3161-73. PubMed ID: 23686764
[TBL] [Abstract][Full Text] [Related]
25. Predicting the Effect of CYP3A Inducers on the Pharmacokinetics of Substrate Drugs Using Physiologically Based Pharmacokinetic (PBPK) Modeling: An Analysis of PBPK Submissions to the US FDA.
Wagner C; Pan Y; Hsu V; Sinha V; Zhao P
Clin Pharmacokinet; 2016 Apr; 55(4):475-83. PubMed ID: 26369776
[TBL] [Abstract][Full Text] [Related]
26. Prediction of Drug-Drug Interactions with Crizotinib as the CYP3A Substrate Using a Physiologically Based Pharmacokinetic Model.
Yamazaki S; Johnson TR; Smith BJ
Drug Metab Dispos; 2015 Oct; 43(10):1417-29. PubMed ID: 26180127
[TBL] [Abstract][Full Text] [Related]
27. Comprehensive PBPK Model of Rifampicin for Quantitative Prediction of Complex Drug-Drug Interactions: CYP3A/2C9 Induction and OATP Inhibition Effects.
Asaumi R; Toshimoto K; Tobe Y; Hashizume K; Nunoya KI; Imawaka H; Lee W; Sugiyama Y
CPT Pharmacometrics Syst Pharmacol; 2018 Mar; 7(3):186-196. PubMed ID: 29368402
[TBL] [Abstract][Full Text] [Related]
28. Assessment of cytochrome P450-mediated drug-drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation.
Lu C; Suri A; Shyu WC; Prakash S
Biopharm Drug Dispos; 2014 Dec; 35(9):543-52. PubMed ID: 25264242
[TBL] [Abstract][Full Text] [Related]
29. Physiologically based pharmacokinetic modeling to predict drug-drug interactions involving inhibitory metabolite: a case study of amiodarone.
Chen Y; Mao J; Hop CE
Drug Metab Dispos; 2015 Feb; 43(2):182-9. PubMed ID: 25324279
[TBL] [Abstract][Full Text] [Related]
30. Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model.
Freise KJ; Shebley M; Salem AH
J Clin Pharmacol; 2017 Jun; 57(6):796-804. PubMed ID: 28052338
[TBL] [Abstract][Full Text] [Related]
31. Application of Physiologically Based Pharmacokinetic Modeling to the Understanding of Bosutinib Pharmacokinetics: Prediction of Drug-Drug and Drug-Disease Interactions.
Ono C; Hsyu PH; Abbas R; Loi CM; Yamazaki S
Drug Metab Dispos; 2017 Apr; 45(4):390-398. PubMed ID: 28167538
[TBL] [Abstract][Full Text] [Related]
32. Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis.
Gupta N; Hanley MJ; Venkatakrishnan K; Bessudo A; Rasco DW; Sharma S; O'Neil BH; Wang B; Liu G; Ke A; Patel C; Rowland Yeo K; Xia C; Zhang X; Esseltine DL; Nemunaitis J
J Clin Pharmacol; 2018 Feb; 58(2):180-192. PubMed ID: 28800141
[TBL] [Abstract][Full Text] [Related]
33. Application of a "Fit for Purpose" PBPK Model to Investigate the CYP3A4 Induction Potential of Enzalutamide.
Narayanan R; Hoffmann M; Kumar G; Surapaneni S
Drug Metab Lett; 2016; 10(3):172-179. PubMed ID: 27604990
[TBL] [Abstract][Full Text] [Related]
34. Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin.
Quinney SK; Zhang X; Lucksiri A; Gorski JC; Li L; Hall SD
Drug Metab Dispos; 2010 Feb; 38(2):241-8. PubMed ID: 19884323
[TBL] [Abstract][Full Text] [Related]
35. Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration-Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics.
Song L; Zhang Y; Jiang J; Ren S; Chen L; Liu D; Chen X; Hu P
Clin Pharmacokinet; 2018 Oct; 57(10):1307-1323. PubMed ID: 29626326
[TBL] [Abstract][Full Text] [Related]
36. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions.
Obach RS; Walsky RL; Venkatakrishnan K; Gaman EA; Houston JB; Tremaine LM
J Pharmacol Exp Ther; 2006 Jan; 316(1):336-48. PubMed ID: 16192315
[TBL] [Abstract][Full Text] [Related]
37. Simulations of Cytochrome P450 3A4-Mediated Drug-Drug Interactions by Simple Two-Compartment Model-Assisted Static Method.
Iga K; Kiriyama A
J Pharm Sci; 2017 May; 106(5):1426-1438. PubMed ID: 28089686
[TBL] [Abstract][Full Text] [Related]
38. Strategy for CYP3A Induction Risk Assessment from Preclinical Signal to Human: a Case Example of a Late-Stage Discovery Compound.
Mao J; Fan P; Wong S; Wang J; Ismaili MHA; Dean B; Hop CECA; Wright M; Chen Y
Pharm Res; 2017 Nov; 34(11):2403-2414. PubMed ID: 28815392
[TBL] [Abstract][Full Text] [Related]
39. Dealing with the complex drug-drug interactions: towards mechanistic models.
Varma MV; Pang KS; Isoherranen N; Zhao P
Biopharm Drug Dispos; 2015 Mar; 36(2):71-92. PubMed ID: 25545151
[TBL] [Abstract][Full Text] [Related]
40. Physiologically based pharmacokinetic modeling to assess metabolic drug-drug interaction risks and inform the drug label for fedratinib.
Wu F; Krishna G; Surapaneni S
Cancer Chemother Pharmacol; 2020 Oct; 86(4):461-473. PubMed ID: 32886148
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
